Skip to main content
. 2016 Jun 20;9:3661–3669. doi: 10.2147/OTT.S96427

Figure 4.

Figure 4

Comparison of long-term OS in refractory AML (A) and middle-and-high-risk MDS (B) patients administered the new and conventional priming regimen.

Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; OS, overall survival.